COMMUNIQUÉS West-GlobeNewswire

Changes in Oriola's Group Management Team

07/07/2017 - 10:00

Oriola Corporation Stock Exchange Release 7 July 2017 at 11.00 Changes in Oriola's Group Management Team Page Content Anders Torell (b. 1967), M.Sc.Eng., has been appointed Vice President of Oriola's Consumer Business [...]

Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017

07/07/2017 - 08:27

Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017 Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 7, 2017 -- Curetis N.V. (the " Company " and, together with Curetis GmbH [...]

Zealand Pharma A/S convenes an extraordinary general meeting 2017

07/07/2017 - 07:55

Zealand Pharma A/S indkalder til ekstraordinær generalforsamling 2017 Zealand Pharma A/S convenes an extraordinary general meeting 2017 Indkaldelse til ekstraordinær generalforsamling i Zealand Pharma A/S (CVR-nr. 20 04 [...]

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)

07/07/2017 - 07:00

July 7, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]

Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S.

06/07/2017 - 23:17

Company announcement - No. 25/2017 Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S. Zealand has today filed a registration statement for the proposed initial public [...]

VALNEVA : Déclaration d'actions et de droits de vote - Juin 2017

06/07/2017 - 18:00

VALNEVA Déclaration d'actions et de droits de vote - JUIN 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon, Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]

VALNEVA : Bilan semestriel du contrat de liquidité

06/07/2017 - 18:00

Paris, le 6 juillet 2017 Bilan semestriel du contrat de liquidité VALNEVA contracté avec NATIXIS Au titre du contrat de liquidité confié à NATIXIS portant sur les actions de la société VALNEVA, à la date du 30 juin 2017 [...]

Weifa ASA: Invitation to presentation of Weifa's Q2 2017 results, Thursday 13 July 2017

06/07/2017 - 15:40

Oslo, 6 July 2017 Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its second quarter and first half 2017 results on Thursday 13 July 2017. The results will be presented by Weifa's CEO [...]

CrownBio Demonstrates Scientific Advancements in Metabolic Disease with a validated and improved translatable model for obesity and Type 2 Diabetes drug discovery

06/07/2017 - 14:00

SANTA CLARA, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company [...]

ProMIS(TM) Neurosciences' Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research

06/07/2017 - 13:30

TORONTO and CAMBRIDGE, Mass., July 06, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today [...]

Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A

06/07/2017 - 13:00

Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A [...]

Targovax ASA: Registration of share capital increase following the private placement

06/07/2017 - 11:06

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis

06/07/2017 - 08:51

Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx ® versus Stelara ® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to-severe scalp psoriasis[1 [...]

Shire plc : Additional Listing

06/07/2017 - 08:00

Additional Listing July 6, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") hereby notifies the market that an application has been made to the London Stock Exchange and the UK Listing Authority for a total of [...]

MITHRA STRENGTHENS E4 PATENT POSITION IN AUSTRALIAN MARKET

06/07/2017 - 07:30

PRESS RELEASE MITHRA StRENGTHENS E4 PATENT POSITION in australiaN MARKET Patents granted for Estetrol (E4) synthesis protect manufacturing process until 2032 Certificate of grant covers E4's use alone as an emergency [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

06/07/2017 - 07:00

pdf version of the press release This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

06/07/2017 - 07:00

Study reports test could reduce invasive diagnostic procedures by 77% NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 6, 2017 - MDxHealth SA (Euronext: MDXH. [...]

MDxHealth lance AssureMDx, un test de biopsie liquide pour la détection du cancer de la vessie

06/07/2017 - 07:00

Une étude révèle que le test pourrait réduire les techniques invasives de diagnostic de 77 % COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, and HERSTAL, BELGIQUE - 07:00 CEST, 6 [...]

Le candidat-médicament QRX-411 de ProQR pour le syndrome d'Usher obtient la désignation d'Orphan Drug (médicament orphelin) de la FDA et de l'EMA

06/07/2017 - 00:44

Principaux résultats Le QRX-411 de ProQR obtient la désignation Orphan Drug (médicament orphelin) par la FDA et l'EMA pour le traitement de la rétinite pigmentaire, y compris le syndrome d'Usher, le sous-type ciblé par [...]